AN2 Therapeutics, Inc.
corporate_fare Company Profile
AN2 Therapeutics, Inc. (NASDAQ:ANTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ANTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for ANTX spans 10-Q, 8-K, DEF 14A, 424B3.
Recent high-impact activity:
- AN2 10-Q: Q3 Loss Narrows to $8.0M, $80.2M Cash, Material Weaknesses Persist
- FDA Clears IND for Oral Epetraborole Phase 2 in Polycythemia Vera; Trial Starts Q4
- AN2 Therapeutics Q2 Loss Widens to $8.2M on Higher R&D; Cash Runway into 2029
- AN2 Therapeutics Flags Ongoing Internal Control Weaknesses
- AN2 Therapeutics Reports Q2 2026 Results, Extends Cash Runway into 2029, and Plans Three Phase 2 Programs by Year-End
Financial Snapshot
Short Interest & Short Volume
9.18 days to coverFINRA reported short interest of 2,440,372 shares in ANTX as of the October 30, 2026 settlement, a 15.5% decrease from the prior period — about 9.2 days to cover at its recent average daily volume. On November 20, 2026, 70.4% of ANTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.